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 The	  purpose	  of	  this	  study	  is	  to	  explore	  the	  strategic	  orientation	  of	  big	  pharma	  in	  bottom-­‐of-­‐the-­‐pyramid	  markets	  (BOP)	  and	  also	  examine	  the	  financial	  viability	  of	  these	  strategies.	  Western	  pharmaceutical	  markets	  have	  continued	  to	  decline	  and	  are	  expected	  to	  grow	  by	  a	  paltry	  3%	  under	  conditions	  of	  depleted	  drug	  pipelines,	  aging	  populations,	  shareholder	  expectations	  and	  pressure	  reform	  the	  delivery	  of	  healthcare.	  On	  the	  other	  hand,	  BOP	  markets	  are	  growing	  at	  14%	  and	  have	  5	  billion	  people	  representing	  65%	  of	  the	  world’s	  population	  and	  a	  market	  power	  of	  $5	  trillion.	  However,	  most	  people	  in	  BOP	  economies	  live	  on	  US$3	  per	  day,	  in	  addition	  to	  deep	  economic,	  social	  and	  political	  instability.	  This	  calls	  for	  a	  new	  business	  model	  to	  tap	  into	  their	  potential,	  despite	  the	  obstacles.	  A	  viable	  value	  creating	  BOP	  strategic	  orientation	  for	  big	  pharma	  will	  require	  an	  entrepreneurial	  mindset,	  innovation	  through	  co-­‐creation,	  multiple	  developmental	  pathways,	  scalable	  and	  adaptable	  logistics,	  creative	  marketing	  through	  a	  new	  price-­‐performance	  envelope	  that	  emphasizes	  volume	  rather	  than	  margins	  and	  utilization	  of	  native	  marketing	  resources	  and	  collaboration	  with	  local	  institutions.	  Data	  on	  strategic	  orientation	  of	  big	  pharma	  with	  respect	  to	  BOP	  markets	  will	  be	  extracted	  from	  annual	  letters	  to	  the	  shareholders	  using	  a	  novel	  method	  of	  historiometry.	  Sanitized	  letters	  will	  be	  rated	  by	  students	  with	  business	  training	  to	  evaluate	  strategic	  orientation	  of	  each	  firm.	  The	  ratings	  will	  be	  completed	  on	  a	  Likert	  scale	  questionnaire	  for	  further	  regression	  analysis.	  In	  addition,	  the	  study	  will	  analyze	  the	  financial	  viability	  of	  BOP	  markets	  relative	  to	  developed	  markets	  using	  archival	  data	  from	  S	  &	  P	  Capital	  IQ	  database.	  The	  study	  will	  contribute	  to	  identifying	  effective	  strategies	  suitable	  for	  BOP	  markets	  and	  also	  provide	  a	  business	  case	  for	  investing	  in	  such	  markets.	  In	  order	  for	  big	  pharma	  to	  sustain	  competitiveness,	  there	  will	  be	  a	  need	  to	  pay	  more	  attention	  to	  BOP	  markets.	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